What T2D Therapy Have You Considered for Your Patients After Metformin?
41m
·
ClinicalXchange Internal Medicine podcasts
·
How common is treatment inertia in the treatment of adult patients with T2D and what can be done about it? Join a multidisciplinary panel including Jim Gavin, MD, PhD; Steve Vacalis, DO; and Jodi Strong, DNP, CDE, BC-ADM, CPT as they discuss and share their insights on the issues surrounding therapeutic inertia. They will also evaluate when to use a GLP-1 RA, and a clinical trial comparing the efficacy and safety of a GLP-1 RA versus a DPP-4i.
This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.
Faculty Presenters:
James R. Gavin III, MD, PhD
Clinical Professor of Medicine, Emory University
Chief Medical Officer, Healing Our Village, Inc.
Atlanta, Georgia
Jodi Strong, DNP, CDCES, BC-ADM, CPT
Aspirus Medical Group
Stevens Point, Wisconsin
Steve Vacalis, DO
Senior Lead Physician
CaroMont Family Medicine, CaroMont Regional Medical Center
Gastonia, North Carolina
The episode What T2D Therapy Have You Considered for Your Patients After Metformin? from the podcast ClinicalXchange Internal Medicine podcasts has a duration of
41:32. It was first published
More episodes from ClinicalXchange Internal Medicine podcasts
What T2D Therapy Have You Considered for Your Patients After Metformin?
How common is treatment inertia in the treatment of adult patients with T2D and what can be done about it? Join a multidisciplinary panel including Jim Gavin, MD, PhD; Steve Vacalis, DO; and Jodi Strong, DNP, CDE, BC-ADM, CPT as they discuss and share their insights on the issues surrounding therapeutic inertia. They will also evaluate when to use a GLP-1 RA, and a clinical trial comparing the efficacy and safety of a GLP-1 RA versus a DPP-4i.
This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.
Faculty Presenters:
James R. Gavin III, MD, PhD
Clinical Professor of Medicine, Emory University
Chief Medical Officer, Healing Our Village, Inc.
Atlanta, Georgia
Jodi Strong, DNP, CDCES, BC-ADM, CPT
Aspirus Medical Group
Stevens Point, Wisconsin
Steve Vacalis, DO
Senior Lead Physician
CaroMont Family Medicine, CaroMont Regional Medical Center
Gastonia, North Carolina
How to Empower Patients with T2D Knowledge and Introduce a GLP-1 RA
What do you need to know about a once-daily GLP-1 RA and what can you do to help your patients taking this T2D therapy? Join this multidisciplinary discussion with Jim Gavin, MD; Curtis Triplitt, PharmD; and Jeffrey Unger, MD, as they review the mechanism of action, dosing, efficacy, and safety of a once-daily GLP-1 RA for adult patients with T2D.
This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.
Faculty Presenters:
James R. Gavin III, MD, PhD
Clinical Professor of Medicine, Emory University
Chief Medical Officer, Healing Our Village, Inc.
Atlanta, Georgia
Jeff Unger, MD, FAAFP, FACE
Diplomate, American Board of Family Practice
Assistant Clinical Professor of Family Medicine, UC Riverside School of Medicine
Riverside, California
Director, Unger Concierge Primary Care Medical Group
Rancho Cucamonga, California
Curtis L. Triplitt, PharmD, CDCES, FADCES
Clinical Associate Professor of Medicine Division of Diabetes
University of Texas Health at San Antonio
Texas Diabetes Institute, part of the University Health System
San Antonio, Texas
COPD Exacerbations: A Clinical Conversation
Faculty:
Neil Skolnik, MD
Family Physician & Professor of Family & Community Medicine
Sidney Kimmel Medical College,
Thomas Jefferson University
Corinne Young, FNP-C, FCCP
Nurse Practitioner
Pulmonary, Critical Care, and Sleep Medicine
Colorado Springs Pulmonary Consultants, PC
Could This GLP-1 RA be Right for Your Adult Patients With T2D?
This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.
Faculty Presenters:
James R. Gavin III, MD, PhD
Clinical Professor of Medicine, Emory University
Chief Medical Officer, Healing Our Village, Inc.
Atlanta, Georgia
Robert Busch, MD
Director of Clinical Research
Albany Med Faculty Practice, Community Endocrine Group
Albany, New York
Pablo F. Mora, MD, FACE, MSc, CDCES
Endocrinologist, North Texas Diabetes & Endocrinology
Clinical Professor, Division of Endocrinology at University of Texas Southwestern Medical Center
Dallas, Texas
Statin Wars
Rita F. Redberg MD, MSc, FACC
Professor of Medicine
Araxe Vilensky Endowed Chair in Cardiology
Faculty, Philip R Lee Institute for Health Policy Studies
Editor, JAMA Internal Medicine
Director, Inquiry Program
UCSF Division of Cardiology
San Francisco, CA
Nearly one-fourth of American adults take lipid-lowering statin medications. However, more people may be eligible. Statin Wars continue to be underway over whether statins should be used not just for the secondary prevention of cardiovascular disease (CVD), but also primary prevention.
Event Sponsors
This event is sponsored by Clinical Care Solutions and is not sponsored by industry.